Combined Effect of Transcranial Direct Current Stimulation (tDCS) and Physical Activity on Gait and Functional Mobility in Participants With Multiple Sclerosis

Multiple Sclerosis Clinical Trial

Official title:

Study of the Combined Effect of Transcranial Direct Current Stimulation (tDCS) and Physical Activity on Gait and Functional Mobility in Participants With Multiple Sclerosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03658668
• Other study ID #: 18-00534
• Status: Completed
• Phase: N/A
• Start date: October 3, 2018
• Est. completion date: June 10, 2021

Study information

• Verified date: July 2023
• Source: NYU Langone Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is aimed to test the efficacy of transcranial direct current stimulation (tDCS) combined with a physical activity (PA) program, in 80 individuals affected by Multiple Sclerosis (MS). In particular, this study will evaluate the efficacy of tDCS when administered simultaneously with PA on walking, functional mobility, and fatigue.

The subjects enrolled will be randomly assigned to the active group (active tDCS+PA) or the sham group (sham tDCS+PA).

Portions of this study may be completed remotely.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: June 10, 2021
• Est. primary completion date: June 10, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Stable and continuous access to internet service at home

• Adequate home facilities (enough space, access to quiet and distraction free area)

• Definite MS diagnosis, subtype relapsing-remitting (RR-MS)

• Disability Status Scale (EDSS) from 1 to 6.5 with clinically significant gait deviations

• Clinically stable and stable on treatment with disease modifying agents at least from 6 months

• Able to independently walk with or without an assisting device (i.e. cane, crutches or walking frames) for medium-long distance

• Absence of other associated medical conditions that would prevent participants from performing physical activity, such as cardiorespiratory and severe osteoarticular disorders

• Able to use study equipment

• Able to commit 10 consecutive daily sessions of tDCS while performing physical program with baseline and follow-up visits

• Able to understand the informed consent process and provide consent to participate in the study

Exclusion Criteria:

• Visual, auditory and motor deficits that would prevent full ability to understand study, as judged by treating neurologist or study staff

• Primary psychiatric disorder that would influence ability to participate

• Receiving current treatment for epilepsy

• Uncontrolled headaches and migraines. In addition, if a subject has had a change in the rate or severity of head pressure, headache, or migraine in the past two weeks, they are excluded

• History of head trauma (e.g., head injury, brain surgery) or medical device implanted in the head (such as Deep Brain Stimulator) or in the neck (such as a Vagus Nerve Stimulator)

• Any skin disorder/sensitive skin (e.g., eczema, severe rashes), blisters, open wounds, burn including sunburns, cuts or irritation, or other skin defects which compromise the integrity of the skin at or near stimulation locations (where electrodes are placed)

• Treatment for a communicable skin disorder currently or over the past 12 months

• History of uncontrolled or labile hypertension

• Other serious uncontrolled medical condition (e.g. cancer or acute myocardial infarction)

• Wide Range Achievement Test-4th Edition (WRAT-4) Reading Recognition score < 85

• History of clinically significant abnormalities on electrocardiogram (EKG)

• Presence of chronic medical illness and/or severe ataxia

• Botulinum toxin injection within the past 4 months or functional surgery in the past 6 months

• Alcohol or other substance use disorder

• Pregnant or breastfeeding

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

Intervention

Device:
• active tDCS
tDCS is a therapeutic treatment that utilizes low amplitude direct currents (<4 mA) to induce changes in cortical excitability.
• sham tDCS
During a sham session, the device is programmed to ramp up to the desired intensity (target 2.5 mA) and ramp down for the initial 60 seconds, with no current delivery during the session, and then again at the end of the session. These brief periods of stimulation serve to mimic the effects of a true stimulation session.

Other:
• Physical Activity (PA)
20 minutes of cycling on an ergonomic cross-trainer

Locations

Country	Name	City	State
United States	New York University School of Medicine	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
NYU Langone Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Gait Velocity	Measured by a 10 meter walk test using wearable inertial sensors	Baseline, Follow-Up Visit (3 days after final treatment session, up to 4 weeks)
Primary	Change in Stride Length	Measured by a 10 meter walk test using wearable inertial sensors	Baseline, Follow-Up Visit (3 days after final treatment session, up to 4 weeks)
Secondary	Percent of tDCS Sessions Completed		End of Final Treatment Session (Up to Week 3)
Secondary	Change in 12-item Multiple Sclerosis Walking Scale Score	12-item questionnaire assessing how multiple sclerosis (MS) affects walking abilities. Items are ranked on a scale from 1 (not at all) to 5 (extremely). The total score is the sum of responses and ranges from 12 to 60; higher scores indicate greater impact of MS on walking abilities.	Baseline, Follow-Up Visit (3 days after final treatment session, up to 4 weeks)
Secondary	Change 21-item Modified Fatigue Impact Scale Score	21-item questionnaire assessing how fatigue may affect a person. Items are ranked on a scale from 0 (never) to 4 (almost always). The total score is the sum of responses and ranges from 0 to 84; scores indicate greater impact of fatigue.	Baseline, Follow-Up Visit (3 days after final treatment session, up to 4 weeks)